Ustekinumab: The "new Kid on the Block" in the Treatment of Psoriatic Arthritis

Drug Development Research

Volumn 76, Issue 8, 2015, Pages 428-431

  Torres, Tiago ^a,b   Faria, Raquel ^a,b  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

IL12 IL23; psoriasis; psoriatic arthritis; Ustekinumab

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ARTICLE; DACTYLITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTHESITIS; FIBROBLAST; HUMAN; MACROPHAGE; PSORIATIC ARTHRITIS; TH17 CELL; TREATMENT DURATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ARTHRITIS, PSORIATIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; USTEKINUMAB;

EID: 84955177415     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21279     Document Type: Article

References (22)

1. Biggioggero M, Favalli EG., 2014. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 75 (Suppl 1): S38-41.
2. Cingoz O., 2009. Ustekinumab. MAbs 1: 216-221.
3. Day MS, Nam D, Goodman S, Su EP, Figgie M., 2012. Psoriatic arthritis. J Am Acad Orthop Surg 20: 28-37.
4. Di Cesare A, Di Meglio P, Nestle FO., 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-1350.
5. Felson DT, LaValley MP., 2014. The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. Arthritis Res Ther 16: 101.
6. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P., 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (Suppl 2): ii14-ii17.
7. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A., 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373: 633-640.
8. Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B., 2014. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 73: 414-419.
9. Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K, Fakharzadeh S, Calabro S, Chevrier M, et al., 2015. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015 May 13.
10. Kang EJ, Kavanaugh A., 2015. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis 6: 194-203.
11. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, et al., 2014. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73: 1000-1006.
12. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, et al., 2015. Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: Results from the PSUMMIT 1 trial. Arthritis Care Res (Hoboken). 2015 Jun 19.
13. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M., 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356: 580-592.
14. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A., 2010. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62: 2876-2885.
15. McGonagle D, Ash Z, Dickie L, McDermott M, Aydin SZ., 2011. The early phase of psoriatic arthritis. Ann Rheum Dis 70 (Suppl 1): i71-i76.
16. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, et al., 2013. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382: 780-789.
17. Mease PJ., 2011. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 70 (Suppl 1): i77-i84.
18. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, et al., 2013. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 168: 844-854.
19. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, et al., 2015. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14: 706-714.
20. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, et al., 2014. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73: 990-999.
21. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, et al., 2011. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306: 864-871.
22. Weitz JE, Ritchlin CT., 2014. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Exp Opin Biol Ther 14: 515-526.